Abbott to Acquire Alere for $5.8B | GenomeWeb

NEW YORK (GenomeWeb) – Abbott has entered into a definitive agreement to acquire Alere for $5.8 billion, the companies said today.

"The combination of Alere and Abbott will create the world's premier point-of-care testing business and significantly strengthen and grow Abbott's diagnostics presence," Miles White, Abbott's chairman and CEO, said in a statement.

On a conference call to discuss the transaction, he also noted, "The trends in point-of-care testing, which we're well aware of, make this the right time to make the move."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.